China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round, raising RMB 600 million (USD 88.5 million). The funding was led by China Structural Reform Fund, with contributions from China State-owned Enterprise Mixed Ownership Reform Fund, CCB PE, Technology Financial Group, and Guolian Group. The proceeds will be used to support novel biologics studies, clinical trials, and licensing-in programs.
Company Overview and Pipeline
CR Biopharma, the biologics division of China Resources Pharmaceutical Group, has established itself as a leader in the biopharmaceutical sector. The company currently has three products on the market and over 20 product pipelines in various stages of development. CR Biopharma’s innovation capabilities span the entire cycle from molecular discovery, process development, translational medicine, and clinical development to commercial production and drug development.
Future Outlook
The Series B financing round marks a significant milestone for China Resources Biopharmaceutical, providing the necessary capital to accelerate its pipeline of innovative biologics. With robust financial backing and a proven track record in drug development, CR Biopharma is poised to make a meaningful impact in the biopharmaceutical industry. The company’s commitment to advancing novel therapies underscores its dedication to improving patient outcomes and addressing significant unmet needs in healthcare.-Fineline Info & Tech
